PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
10.36%
Some net income increase while AGEN is negative at -16.17%. John Neff would see a short-term edge over the struggling competitor.
-22.93%
Both reduce yoy D&A, with AGEN at -1.62%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
18.38%
Some yoy growth while AGEN is negative at -44.59%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
-40.28%
Both cut yoy SBC, with AGEN at -28.96%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
112.09%
Well above AGEN's 143.67% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
86.72%
Lower AP growth vs. AGEN's 1595.30%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
300.21%
Growth well above AGEN's 59.02%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
-40.28%
Negative yoy while AGEN is 63.92%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
17.79%
Operating cash flow growth above 1.5x AGEN's 4.51%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
19.38%
CapEx growth well above AGEN's 2.88%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
99.99%
Less 'other investing' outflow yoy vs. AGEN's 199900.00%. David Dodd would see a stronger short-term cash position unless competitor invests more wisely.
98.29%
Lower net investing outflow yoy vs. AGEN's 251.67%, preserving short-term cash. David Dodd would confirm expansions remain sufficient.
No Data
No Data available this quarter, please select a different quarter.
684.38%
We slightly raise equity while AGEN is negative at -100.00%. John Neff sees competitor possibly preserving share count or buying back shares.
No Data
No Data available this quarter, please select a different quarter.